Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Ablynx Builds Case For AbbVie Option On Humira Successor

Executive Summary

Clinical data shows Ablynx's anti-IL 6R vobarilizumab (ALX0061) to have efficacy in the same range as Roche's Actemra as a monotherapy for rheumatoid arthritis. With more data due shortly, Ablynx is confident that AbbVie will exercise its option for the product.

Advertisement

Related Content

AbbVie Knocks Back Ablynx's Vobarilizumab In RA
Deal Watch: AZ Ups mRNA Stake, Gilead's HIV Innovation, Hospira Returns Lucentis Biosimilar, Pfizer/Takeda End Distribution Deal
Galapagos Soothed By Gilead's $725m Up Front For AbbVie Reject Filgotinib
Did Money Motivate AbbVie's Galapagos Decision?
AbbVie RA deal: best in class – but years behind

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC065609

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel